Get the Stockscreener App
38.65
2.05%
-0.81
After Hours:
38.65
Royalty Pharma Plc stock is traded at $38.65, with a volume of 3.80M.
It is down -2.05% in the last 24 hours and up +4.43% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$39.46
Open:
$39.53
24h Volume:
3.80M
Relative Volume:
0.93
Market Cap:
$16.71B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.83
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
-2.37%
1M Performance:
+4.43%
6M Performance:
+12.85%
1Y Performance:
+48.60%
1-Day Range:
$37.77
$39.69
1-Week Range:
$37.77
$40.01
52-Week Range:
$24.05
$41.24
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
38.65 | 16.86B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Why Royalty Pharma plc (RPD) stock could break out in 2025Quarterly Profit Summary & Risk Controlled Daily Plans - newser.com
What macro factors could drive Royalty Pharma plc (RPD) stock higher2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Will Royalty Pharma plc (RPD) stock maintain strong growthTrend Reversal & Precise Buy Zone Identification - newser.com
Royalty Pharma Insider Sold Shares Worth $2,735,329, According to a Recent SEC Filing - MarketScreener
Historical volatility pattern of Royalty Pharma plc visualizedTrade Exit Summary & Expert Curated Trade Ideas - newser.com
Will Royalty Pharma plc (RPD) stock hit Wall Street targetsBond Market & Long-Term Growth Portfolio Plans - newser.com
Trading the Move, Not the Narrative: (RPRX) Edition - news.stocktradersdaily.com
Is Royalty Pharma plc (RPD) stock attractive post correctionWall Street Watch & Risk Managed Investment Signals - newser.com
Analyzing net buyer seller activity in Royalty Pharma plcJuly 2025 Summary & Verified Technical Signals - newser.com
How Royalty Pharma plc (RPD) stock compares with top peersWeekly Stock Analysis & Safe Capital Investment Plans - newser.com
Can Royalty Pharma plc stock rebound after recent weaknessWeekly Market Report & High Accuracy Investment Signals - newser.com
Top chart patterns to watch in Royalty Pharma plcBull Run & Safe Capital Growth Plans - newser.com
Why analysts remain bullish on Royalty Pharma plc stockShare Buyback & Capital Efficient Trading Techniques - newser.com
Applying chart zones and confluence areas to Royalty Pharma plcQuarterly Risk Review & Daily Risk Controlled Trade Plans - newser.com
Royalty Pharma (RPRX): Is the Stock Undervalued After Higher 2025 Revenue Guidance and Major Buyback Completion? - Yahoo Finance
How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves - Yahoo Finance UK
Vise Technologies Inc. Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Ontario Teachers Pension Plan Board Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Published on: 2025-11-18 06:12:54 - newser.com
Why retail investors pile into Royalty Pharma plc stockJuly 2025 Recap & Capital Protection Trade Alerts - newser.com
Forsta AP Fonden Reduces Stake in Royalty Pharma PLC $RPRX - MarketBeat
Geode Capital Management LLC Has $299.49 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
What indicators show strength in Royalty Pharma plc2025 Macro Impact & Low Drawdown Momentum Ideas - newser.com
What analysts say about Royalty Pharma plc stockShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - earlytimes.in
What’s the recovery path for long term holders of Royalty Pharma plc - newser.com
What MACD signals say about Royalty Pharma plcTrade Risk Assessment & Low Risk High Reward Ideas - newser.com
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):